ATE223574T1 - Verbesserungen in zusammenhang mit screeningverfahren - Google Patents

Verbesserungen in zusammenhang mit screeningverfahren

Info

Publication number
ATE223574T1
ATE223574T1 AT96926484T AT96926484T ATE223574T1 AT E223574 T1 ATE223574 T1 AT E223574T1 AT 96926484 T AT96926484 T AT 96926484T AT 96926484 T AT96926484 T AT 96926484T AT E223574 T1 ATE223574 T1 AT E223574T1
Authority
AT
Austria
Prior art keywords
sbp
display
members
disclosed
viral
Prior art date
Application number
AT96926484T
Other languages
English (en)
Inventor
Stephen James Russell
Frances Joanne Morling
Kah-Whye Peng
Original Assignee
Biofocus Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofocus Discovery Ltd filed Critical Biofocus Discovery Ltd
Application granted granted Critical
Publication of ATE223574T1 publication Critical patent/ATE223574T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
AT96926484T 1995-08-05 1996-08-05 Verbesserungen in zusammenhang mit screeningverfahren ATE223574T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9516138.6A GB9516138D0 (en) 1995-08-05 1995-08-05 Improvements in or relating to methods of screening substances
PCT/GB1996/001905 WO1997006435A1 (en) 1995-08-05 1996-08-05 Improvements in or relating to methods of screening substances

Publications (1)

Publication Number Publication Date
ATE223574T1 true ATE223574T1 (de) 2002-09-15

Family

ID=10778860

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96926484T ATE223574T1 (de) 1995-08-05 1996-08-05 Verbesserungen in zusammenhang mit screeningverfahren

Country Status (8)

Country Link
EP (1) EP0842426B1 (de)
JP (1) JPH11510696A (de)
AT (1) ATE223574T1 (de)
AU (1) AU710446B2 (de)
CA (1) CA2225680A1 (de)
DE (1) DE69623480D1 (de)
GB (1) GB9516138D0 (de)
WO (1) WO1997006435A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022972A2 (en) * 1995-12-15 1997-06-26 Pharmacia & Upjohn Company Method for the simultaneous detection of a therapeutic target for a disease state and its neutralizing antibody-like molecule
US6723512B2 (en) 1997-08-29 2004-04-20 Selective Genetics Inc. Methods using genetic package display for detecting and identifying protein-protein interactions that facilitate internalization and transgene expression and cells or tissues competent for the same and methods for evolving gene delivery vectors
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
EP1009819A1 (de) * 1997-08-29 2000-06-21 Selective Genetics, Inc. Verfahren zur selektion von einfürungsliganden für die abgabe von genen mittels phagendisplay
US6589730B1 (en) 1997-08-29 2003-07-08 Selective Genetics, Inc. Methods for identifying protein-protein interactions by selective transduction
US6451527B1 (en) * 1997-08-29 2002-09-17 Selective Genetics, Inc. Methods using genetic package display for selecting internalizing ligands for gene delivery
ES2207203T3 (es) * 1998-04-17 2004-05-16 Rigel Pharmaceuticals, Inc. Ensayos con parametros multiples facs para detectar alteraciones en parametros celulares.
US8334238B2 (en) 1998-04-17 2012-12-18 Rigel, Inc. Multiparameter FACS assays to detect alterations in cellular parameters and to screen small molecule libraries
WO2000014216A1 (en) * 1998-09-04 2000-03-16 Zk Pharmaceuticals, Inc. Method for selecting peptides inhibiting viral surface protein binding to cell surface receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
DE69333115D1 (de) * 1992-09-22 2003-08-28 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
WO1994027643A1 (en) * 1993-06-01 1994-12-08 Targeted Genetics Corporation Envelope fusion vectors for use in gene delivery
GB9412844D0 (en) * 1994-06-27 1994-08-17 Medical Res Council Improvements in or relating to therapeutic methods

Also Published As

Publication number Publication date
WO1997006435A1 (en) 1997-02-20
EP0842426B1 (de) 2002-09-04
GB9516138D0 (en) 1995-10-04
EP0842426A1 (de) 1998-05-20
CA2225680A1 (en) 1997-02-20
DE69623480D1 (de) 2002-10-10
JPH11510696A (ja) 1999-09-21
AU710446B2 (en) 1999-09-23
AU6664896A (en) 1997-03-05

Similar Documents

Publication Publication Date Title
Denney et al. Human liver MAO-A and MAO-B separated by immunoaffinity chromatography with MAO-B-specific monoclonal antibody
Michalak et al. Localization of the high affinity calcium binding protein and an intrinsic glycoprotein in sarcoplasmic reticulum membranes.
WO1995023859A3 (en) Novel forms of t cells costimulatory molecules and uses therefor
CA2321177A1 (en) Recombinant fibronectin-based extracellular matrix for wound healing
CA2158745A1 (en) Inhibitor of vascular endothelial cell growth factor
NO913186D0 (no) Fremgangsmaate for anvendelse og syntese av peptider.
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
EP0930366A3 (de) Bindungsdomänen des Serrate-proteins
DK1032660T3 (da) Fremgangsmåde til identivicering af bindingsstedsdominans som bevarer evnen til at binde til en epitop
EP0687183A4 (de) Synergistische zusammensetzung bestehend aus einem auf cd4-basierendem protein und anti-hiv-1-antikörper, und methoden zu deren verwendung
DK0412486T3 (da) Antistoffer mod TNF-bindingsprotein I og F(ab)-fragmenter
ATE223574T1 (de) Verbesserungen in zusammenhang mit screeningverfahren
DK0754229T3 (da) Afamin: et humant serum albumin-lignende protein
AU1378395A (en) Metal chelators
WO1997020933A3 (en) Mutational variants of mammalian ob gene proteins
NO962084L (no) DNA sekvens som koder for en BMP reseptor
NZ334518A (en) Homocysteine desulphurase from the protozoan trichomonas vaginalis
CA2240296A1 (en) Endothelial cell proliferation inhibitor and method of use
EP0935754A4 (de) Zusammensetzungen und verfahren zum nachweis der bindung von antikörpern in zellen
WO1996007739A3 (en) Interleukin-1 type 3 receptors
FR2732346B1 (fr) Proteines mutees, codees par un gene env mute de lentivirus, fragments peptidiques inclus dans lesdites proteines, vecteurs d'expression exprimant lesdites proteines mutees et leurs applications
WO2000001820A3 (en) Nucleic acid molecules encoding nuclear hormone receptor coactivators, and uses thereof
EP0738735A3 (de) Typ I Prokollagen aminoterminales Propeptid, dessen Antikörper und Testverfahren unter Verwendung davon
DE69115104D1 (de) Composition comprising at least two different antibodies or fragments thereof.
Weitz et al. Characterization of an active hydrophilic erythrocyte membrane acetylcholinesterase obtained by limited proteolysis of the purified enzyme

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties